Researchers say rapid weight loss from GLP-1 drugs can include significant lean-mass loss, prompting investigation into add-on therapies designed to preserve muscle.
By yourNEWS Media Newsroom
GLP-1 weight-loss drugs have become widely used for obesity and diabetes, but clinical findings are raising concerns that rapid weight loss from the medications may come with a serious tradeoff: the loss of lean muscle mass along with fat.
Drugs such as Ozempic, Wegovy, Mounjaro and other GLP-1 receptor agonists work by reducing appetite, slowing digestion and helping patients feel full for longer periods. The result can be substantial weight loss. But researchers have warned that a meaningful share of that lost weight may come from lean tissue rather than fat alone.
A 2022 clinical trial found that people using Ozempic lost about 23 pounds of fat over 68 weeks, but also lost roughly 15 pounds of lean muscle mass. Researchers say that kind of muscle loss can carry consequences beyond appearance, particularly for older adults or medically fragile patients.
Lean muscle helps support mobility, balance, metabolic health, immune resilience and independence. When muscle mass declines too quickly, patients may face greater risks of frailty, falls, fractures, infection and reduced physical function.
Some research has suggested that roughly one-third of weight lost on GLP-1 medications may come from lean mass. That has prompted doctors and researchers to urge caution, especially for seniors, people with low baseline muscle mass and patients who lose weight rapidly without resistance training or adequate protein intake.
The concern has also fueled debate over whether federal regulators should require clearer warnings about possible muscle and bone loss. The Food and Drug Administration has not mandated specific warnings for muscle or bone atrophy, despite growing discussion among researchers and clinicians about those risks.
The issue has become more urgent as GLP-1 use has expanded. By 2025, about one in eight Americans had used GLP-1 receptor agonists, according to the submitted report, reflecting how quickly the drugs have moved into mainstream treatment for obesity and diabetes.
In addition to physical concerns, some patients have reported mood-related side effects, including depression or emotional dulling. Researchers are still studying whether those symptoms are directly caused by the medications, related to rapid weight loss, connected to dietary changes or driven by other factors.
The muscle-loss problem has led researchers to test whether additional therapies can help preserve lean mass during GLP-1 treatment.
In June 2026, Nature Medicine published results from the phase 2 EMBRAZE trial examining apitegromab, an investigational drug designed to block myostatin, a protein involved in muscle breakdown.
The randomized, double-blind, placebo-controlled trial included 102 adults with overweight or obesity, most of them women. Participants received tirzepatide, the active ingredient in Mounjaro, along with either apitegromab or a placebo.
After 24 weeks, patients who received apitegromab with tirzepatide retained 1.9 kilograms, or about 55%, more lean mass than those who received tirzepatide with placebo. Both groups lost similar amounts of total body weight.
Lean mass accounted for 14.6% of total weight loss in the apitegromab group, compared with 30.2% in the placebo group.
Adverse events were reported at similar rates in both groups, affecting 76% of apitegromab participants and 71% of placebo participants. Serious adverse events occurred in 2% of participants in each group.
Apitegromab remains experimental and is currently available only in clinical trials. It is administered intravenously, though the manufacturer is exploring self-injection options.
Researchers cautioned that larger and longer studies are needed before apitegromab or similar drugs can be recommended widely for patients using GLP-1 medications.
The findings show that the medical community is taking lean-mass loss seriously as GLP-1 drugs continue to reshape obesity treatment. They also underscore that weight loss should not be judged only by the number on a scale.
Clinicians increasingly emphasize that patients using GLP-1 medications should preserve muscle through adequate protein intake, strength training and medical monitoring. For many patients, diet and exercise remain essential parts of treatment rather than optional additions.
The emerging evidence does not mean GLP-1 drugs lack benefit. They have helped many patients lose significant weight and improve diabetes-related measures. But researchers say the benefits must be weighed against risks, especially when rapid fat loss is accompanied by loss of muscle tissue that supports long-term health.
As regulators, physicians and patients continue evaluating the drugs, the central question is no longer simply how much weight GLP-1 users can lose. It is how much of that loss comes from fat, how much comes from muscle and whether the treatment leaves patients healthier, stronger and more resilient over time.
Source: Natural News
Original article
Comments